In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26.

Amgen has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating generalized myasthenia gravis, likely influencing its 14% price increase over the last ...

Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of generalised myasthenia gravis (gMG) patients after 52 weeks in a Phase III trial. Results from the company’s ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with generalized myasthenia gravis. The results ...

Patients were eligible for the study if they had Myasthenia Gravis Foundation of America ... executive vice president of Research and Development at Amgen. “These findings reinforce ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.